PTO/SB/81 (01-06)

## POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

	FTOISBIBT (01:08)
Application Number	10/594,850
Filing Date	
First Named Inventor	ROBBINS, Joan M.
Title	USE OF 5,10-METHYLENE TETRAHYDROFOLATE FOR THE TREATMENT OF CANCER
Art Unit	
Examiner Name	
Attorney Docket Number	022082-000610US

I hereby revoke all pre	evious powers of attorney given	in the abo	ve-identified ap	olication.	
I hereby appoint:					
Practitioners associated with the Customer Number:			20350		
OR					
Practitioner(s) named t	below:	•			
Name			Registration Number		
as my/our attorney(s) or ag Trademark Office connecte	gent(s) to prosecute the application in ed therewith.	dentified abo	ove, and to transac	t all business in t	he United States Patent and
	ge the correspondence address for ociated with the above-mentioned C			on to:	
OR	,				
The address ass	ociated with Customer Number:				
OR					
Firm or Individual Name					
Address					
City			State		Zlp
Country					
Telephone			Email		-
I am the: Applicant/Inventor.	1 - 11-11-1				
	ne entire interest. See 37 CFR 3.71 CFR 3.73(b) is enclosed. (Form P				
	SIGNATURE of Ap	plicant or	Assignee of Rec	ord	
Signature	atrib L			Date (4 J	ure 5007
Name	Patrick Keran, Sieve terry Telephone				
Title and Company	le and Company  ITD V ENTYLY & HALL WA ( CHITCALLS IN (				
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.					
*Total of	forms are submitted.				

STATEMENT UI	NDER 37 CFR 3.73(b)			
Applicant/Patent Owner:				
Application No./Patent No./Control No.: 10/594,850	Filed/Issue Date:			
Entitled: USE OF 5,10-METHYLENE TETRAHYDROFOL	ATE FOR THE TREATMENT OF CANCER			
Adventrx Pharmaceuticals, Inc.	, a Delaware corporation			
	(Type of Assignee: corporation, partnership, university, government agency, etc.)			
states that it is:				
<ol> <li>the assignee of the entire right, title, and interest;</li> </ol>				
<ol> <li>an assignee of less than the entire right, title and (The extent (by percentage) of its ownership inter</li> </ol>				
in the patent application/patent identified above by virtue of	either:			
<ul> <li>A. An assignment from the inventor(s) of the patent applica the United States Patent and Trademark Office at Re assignment is attached.</li> <li>OR</li> </ul>	tion/patent identified above. The assignment was recorded in eel, or a true copy of the original			
B. A chain of title from the inventor(s), of the patent application				
1. From:				
The document was recorded in the United State				
Reel, Frame				
2. From:				
The document was recorded in the United State				
Reel, Frame				
3. From:				
The document was recorded in the United Stat				
Reel, Frame	, or for which a copy thereof is attached.			
Additional documents in the chain of title are listed o	n a supplemental sheet.			
As required by 37 CFR 3.73(b)(1)(i), the documentary evid assignee was, or concurrently is being, submitted for recognise [NOTE: A separate copy (i.e., a true copy of the original Division in accordance with 37 CFR Part 3, to record to 302.08]	ence of the chain of title from the original owner to the ordation pursuant to 37 CFR 3.11 assignment document(s)) must be submitted to Assignment the assignment in the records of the USPTO. See MPEP			
The undersigned (whose title is supplied below) is authorized	-			
Signature				
Jatrick Karan	Date			
Printed or Typed Name	Telephone Number			
Corporate Socretary	·			
Title				

Attorney Docket No.: 022082-000610US

## ASSIGNMENT OF PATENT APPLICATION

WHEREAS, Joan ROBBINS of 10710 Edenoaks St., San Diego, CA 92131; and Mark CANTWELL of 11525 Caminito La Bar, #50, San Diego, CA 92126, hereinafter referred to as "Assignors," are the inventors of the invention described and set forth in the below-identified application for United States Letters Patent:

Title of Invention:

USE OF 5,10-METHYLENE TETRAHYDROFOLATE FOR

THE TREATMENT OF CANCER

Int'l Appln No.:

PCT/US2005/011046

Int'l Filing Date:

April 1, 2005

U.S. Application No.:

10/594,850; and

WHEREAS, Adventry Pharmaceuticals, Inc., a corporation of Delaware, located at 6725 Mesa Ridge Rd., Suite 100, San Diego, CA 92121, hereinafter referred to as "Assignee," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that they will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Daled: The 12 206 Y

JOAN ROBBINS

Dated: 14he 12 2007

MARK CANTWELL

